Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boston Scientific

This article was originally published in The Gray Sheet

Executive Summary

Premarket approval application supplement for NIR-On-Ranger coronary stent with Sox securement system is submitted to FDA July 28, the company says. The submission occurs nearly ten months after the firm voluntarily recalled the product on Oct. 5, 1998 due to higher than anticipated balloon failure rates (1"The Gray Sheet" Oct. 12, 1998, p. 28). Recall of the device commenced eight weeks after its launch

You may also be interested in...



Boston Scientific Relying On Primo In Wake Of NIR-On-Ranger With SOX Recall

Boston Scientific expects to generate $150-175 mil. U.S. stent revenue in the fourth quarter despite the firm's Oct. 5 voluntary recall of the NIR-On-Ranger coronary stent system with the SOX securing system.

Ulta CEO On Target Corp Partnership: ‘Now Is The Time For Innovation In Retail”

Target guests in selected locations will be able to shop a curated Ulta Beauty section in the second half of 2021. The partnership could attract new clientele to Target stores and give Ulta a boost following nationwide store closures this year due to COVID.

COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers

First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.

UsernamePublicRestriction

Register

SC143367

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel